<![CDATA[Preeclampsia is a medical condition that occurs during pregnancy, characterized by high blood pressure and the presence of protein in the urine (proteinuria) after 20 weeks of gestation. This condition poses a risk to pregnant women, fetuses and newborn babies. Mothers with preeclampsia suffer severe morbidity and mortality due to impaired function of organs such as the kidneys and liver, as well as blood clotting problems, which can occur in hypertension in pregnancy. Problems with the placenta and stunted fetal growth are also risks. Therefore, evaluation of the use of antihypertensive drugs is very important. The goal is to ensure that the drugs used are appropriate, effective and safe for pregnant women. This study aims to determine the profile and effectiveness of the use of antihypertensive drugs in inpatient preeclampsia patients at RSIA Sitti Khadijah 1 Makassar. This research uses a non-experimental (observational) descriptive method. The data used is retrospective, namely in the form of secondary data. The data source comes from medical records of inpatients diagnosed with preeclampsia. The research was conducted at RSIA Sitti Khadijah 1 Makassar for the period January 2023 to April 2024. The results of the study showed that the use of antihypertensive drugs in 47 preeclampsia patients, namely nifedipine monotherapy, was 87%, the combination of nifedipine and methyldopa was 9%, the combination of nifedipine and amlodipine was 4%. Most of the antihypertensives used are effective and have achieved the therapy goals of the Queensland Clinical Guideline 2021. Compliance with the use of antihypertensive drugs and doses was achieved at 96%, while 2% were declared inappropriate. As many as 94% were effective in reducing blood pressure according to therapy goals.]]>
